Overview

• ATTAIN-1 randomized about 3,100 adults without diabetes across multiple countries to daily orforglipron at 6, 12, or 36 mg or to placebo for 72 weeks, paired with diet and exercise advice.
• Participants on the highest dose lost roughly 11–12% of body weight on average, with more than half shedding at least 10% and about 18% losing 20% or more.
• Investigators from Barcelona’s Vall d’Hebron reported that approximately three quarters of the weight lost was fat rather than lean mass.
• The study documented improvements in blood pressure, triglycerides, non‑HDL cholesterol and waist circumference alongside weight reduction.
• Common side effects were gastrointestinal, including diarrhea, vomiting and constipation, and the non‑peptidic oral GLP‑1 agent is positioned as an alternative to injectables pending regulatory review.